The Effect Of SVEGF On Paclitaxel And Cisplation Chemotherapy Combined With Aidi Injection In Treatment Of Non-small Lung Cancer

Objective: The therapies of non-small lung cancer are still in difficulties in medicine. The study of traditional herbal medicine which are report to have a good anti-tumor effect is more and profound. Aidi injection is made with addition of Cantharides,Ginseng,Astragalus mongholicus and Acanthopanax .The effect and mechanism of anti-tumor was reported and studies suggessted Aidi injection could suppress cancer in vivo and in vivo of mouse. This experiment will do more clinical research on anti-tumor mechanism of Aidi injection by studies on Aidi's effect on sVEGF in treatment of non-small lung cancer meanwhile ,this experiment do more clinical studies on adverse reactions in the chemotherapy combined with Aidi injection。Methods:31 patients with non-small lung cancer are divided into 2 groups: GroupⅠ(chemotherapy group), GroupⅡ(aidi + chemotherapy group). 15 patients are in GroupⅠ,16 patients are in GroupⅡ. Patients of the first group receive chemotherapy of Paclitaxel and Cisplation . Patients of the secound group receive chemotherapy of Aidi injection.Serum vascular endothelial growth factor (sVEGF) level is detected by sandwith ABC enzyme linked immunosorbant assay before and after treatment. The ELISA kid is produced by American Biosouce Company. The amount of WBC,HB,PLT is detected by the instrument (SYSMEX ST-1800i ).The side effects both leukopenia and gastrointesinal reaction are recorded during this treatment.Result:1. The sVEGF level before treatment: the sVEGF level inⅣperiod is significantly higher thanⅢperiod (P<0.05).2. The changes of sVEGF levels in the patients of GroupⅠandGroupⅡ: there are15 patients in GroupⅠand 16 patients in GroupⅡ. Before treatment the sVEGF levels in GroupⅡhave no significant difference with GroupⅠ(P > 0.05).After treatment the levels of GroupⅡshow significant difference with pretherapy.(p=0.048).The sVEGF levels in GroupⅠafter treatment are sligtly lower than pretherapy(p > 0.05). After treatment,the difference in sVEGF levels between groupⅠand GroupⅡare significant(p=0.035).In GroupⅡthe levels ofⅢperiod are lower than before (P > 0.05),but the levels ofⅣperiod are lower than before(P=0.035).3. Side effects of two groups after treatment: the major side effects were leukopenia and gastrointesinal reaction .Ⅲ+Ⅳleukopenia suppression and gastrointesinal reaction are lower in GroupⅡthan that in GroupⅠ. The effective rates of leukopenia suppression in GroupⅠis 100% and in GroupⅡis 94%(15/16). the effective rates ofⅢ+Ⅳleukopenia suppression in groupⅠand groupⅡare 60%(9/15)and 37%(6/16), P<0.05. the effective rates ofⅢ+Ⅳgastrointesinal reaction in GroupⅠand GroupⅡare 53%(8/15)and 19%(3/16), P<0.05. The effective rates of PLT,Hb don't show remarkbale differenceConclusions:1. The level of sVEGF had no correlation to pathotype but was correlated to TNM stage. And the sVEGF level was higher in advanced stage than the earily stage in patients with non-small lung cancer.2. The sVEGF level in patients with non-small lung cancer was decreased by Aidi injection. The decrease was more remarkable in advanced stage than the earily stage.3. The primary research showed that TP chemotherapy combined with Aidi injection can reduce the adverse reactions of chemotherapy in patients with advanced non-small lung cancer.